Kcnq2-5 channel activator

Abstract

The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.

1 .- 19 . (canceled) 
     
     
         20 . A method for preventing and/or treating a KCNQ2-5 channel-related disease, comprising administering to a mammal in need thereof an effective amount of the compound of general formula (I), a salt thereof, a solvate thereof, or a cocrystal thereof: 
       
         
           
           
               
               
           
         
         wherein X 1  is C—R 6 ; X 2  is C—R 7 ; R 11  is (1) OR 1  or (2) NH 2 ; R 1  is (1) a hydrogen atom or (2) a C1-4 alkyl group; R 2  and R 3  are each independently (1) a hydrogen atom, or (2) a C1-4 alkyl group which may be substituted with halogen, where both R 2  and R 3  are not simultaneously a hydrogen atom; R 4 , R 5 , R 6 , and R 7  are each independently (1) a hydrogen atom, (2) halogen, (3) a C1-4 alkyl group which may be substituted with halogen, or (4) a C1-4 alkoxy group which may be substituted with halogen, where both R 4  and R 5  are not simultaneously a hydrogen atom; Y is —NH—; R 8  is (1) a hydrogen atom or (2) a C1-4 alkyl group which may be substituted with halogen or a hydroxy group; R 9  is (1) a ring A, (2) -C1-4 alkylene group-ring A, (3) -C2-4 alkenylene group-ring A, (4) -C2-4 alkynylene group-ring A, (5) -ring B-ring C, (6) -ring B-C1-4 alkylene group-ring C, (7) -ring B-C2-4 alkenylene group-ring C, (8) -ring B-C2-4 alkynylene group-ring C, or (9) -ring B—O-ring C, where the alkylene group, alkenylene group or alkynylene group each may be substituted with halogen or a hydroxy group; the ring A is (1) C3-8 cycloalkane, (2) 3- to 8-membered heterocycloalkane, (3) a C3-12 monocyclic or bicyclic unsaturated carbocyclic ring, or which may be partially saturated, or (4) 3- to 12-membered monocyclic or bicyclic unsaturated heterocycle including one to four heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom, or which may be partially saturated; ring B and ring C are each independently (1) C3-8 cycloalkane, (2) 3- to 8-membered heterocycloalkane, (3) a C3-7 monocyclic unsaturated carbocyclic ring, or which may be partially saturated, or (4) 3- to 7-membered monocyclic unsaturated heterocycle including one to three heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, or which may be partially saturated; where the ring A, ring B and ring C each independently may be substituted with one to five R 10 , and when a plurality of R 10  is present, the plurality of R 10  may be the same as or different from each other; R 10  is (1) halogen, (2) a hydroxy group, (3) a cyano group, (4) a C1-6 alkyl group which may be substituted with halogen or a hydroxy group, (5) a C1-6 alkoxy group which may be substituted with halogen or a hydroxy group, or (6) an amino group which may be substituted with a C1-4 alkyl group or a C2-5 acyl group. 
       
     
     
         21 . The method according to  claim 20 , wherein the compound is a compound of general formula (II), a salt thereof, a solvate thereof, or a cocrystal thereof: 
       
         
           
           
               
               
           
         
         wherein the symbols have the same meaning as in  claim 20 . 
       
     
     
         22 . The method according to  claim 20 , wherein R 1  is a hydrogen atom, a salt thereof, a solvate thereof, or a cocrystal thereof. 
     
     
         23 . The method according to  claim 20 , wherein one of R 2  and R 3  is a methyl group which may be substituted with halogen, and the other is a hydrogen atom or a methyl group which may be substituted with halogen, a salt thereof, a solvate thereof, or a cocrystal thereof. 
     
     
         24 . The method according to  claim 20 , wherein R 6  is a hydrogen atom or halogen, and R 7  is a hydrogen atom, a salt thereof, a solvate thereof, or a cocrystal thereof. 
     
     
         25 . The method according to  claim 20 , wherein the compound is a compound of general formula (II-1), a salt thereof, a solvate thereof, or a cocrystal thereof: 
       
         
           
           
               
               
           
         
         wherein R 6  is a hydrogen atom or halogen, and the other symbols have the same meaning as in  claim 20 . 
       
     
     
         26 . The method according to  claim 20 , wherein the compound is a compound of general formula (II-2), a salt thereof, a solvate thereof, or a cocrystal thereof: 
       
         
           
           
               
               
           
         
         wherein R 6  is a hydrogen atom or halogen, and the other symbols have the same meaning as in  claim 20 . 
       
     
     
         27 . The method according to  claim 20 , wherein R 4  and R 5  are each independently halogen or a methyl group, a salt thereof, a solvate thereof, or a cocrystal thereof. 
     
     
         28 . The method according to  claim 20 , wherein R 8  is a hydrogen atom or a methyl group, a salt thereof, a solvate thereof, or a cocrystal thereof. 
     
     
         29 . The method according to  claim 20 , wherein the compound, a salt thereof, a solvate thereof, or a cocrystal thereof is:
 (1) 1-{2,6-dichloro-4-[(2R)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}-3-{[5-(trifluoromethyl)-2-pyridinyl]methyl}urea,   (2) 1-{2,6-dichloro-4-[(2R)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}-3-{[5-(trifluoromethyl)-2-pyrimidinyl]methyl}urea,   (3) 1-{2,6-di chloro-4-[(2R)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}-3-{[6-(trifluoromethyl)-3-pyridinyl]methyl}urea,   (4) 1-[(5-chloro-2-pyridinyl)methyl]-3-{2,6-dichloro-4-[(2R)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}urea,   (5) 1-{2,6-dichloro-4-[(2R)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}-3-{[3-(trifluoromethyl)-1,2,4-oxadiazole-5-yl]methyl}urea,   (6) 1-{2,6-dichloro-4-[(2S)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}-3-{[5-(trifluoromethyl)-2-pyrimidinyl]methyl}urea,   (7) 1-{2,6-dichloro-4-[(2S)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}-3-{[6-(trifluoromethyl)-3-pyridinyl]methyl}urea,   (8) 1-{2,6-dichloro-4-[(2S)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}-3-{[3-(trifluoromethyl)-1,2,4-oxadiazole-5-yl]methyl}urea,   (9) 1-{2,6-dichloro-4-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}-3-{[3-(trifluoromethyl)-1,2,4-oxadiazole-5-yl]methyl}urea,   (10) 1-{2,6-dichloro-4-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}-3-{[2-(trifluoromethyl)-5-pyrimidinyl]methyl}urea,   (11) 1-{2,6-dichloro-4-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}-3-{[5-(trifluoromethyl)-2-pyrimidinyl]methyl}urea,   (12) 1-{2,6-dichloro-4-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}-3-{[2-(trifluoromethyl)-1,3-thiazole-5-yl]methyl}urea,   (13) 1-{2,6-dichloro-4-[(1S)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}-3-{[3-(trifluoromethyl)-1,2,4-oxadiazole-5-yl]methyl}urea,   (14) 1-{2,6-dichloro-4-[(1S)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}-3-{[2-(trifluoromethyl)-5-pyrimidinyl]methyl}urea,   (15) 1-{2,6-dichloro-4-[(1 S)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}-3-{[2-(trifluoromethyl)-1,3-thiazole-5-yl]methyl}urea,   (16) 1-{2,6-dichloro-4-[(2S)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}-3-{[5-(trifluoromethyl)-2-pyridinyl]methyl}urea, or   (17) 1-{2,6-dichloro-4-[(1S)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}-3-{[5-(trifluoromethyl)-2-pyrimidinyl]methyl}urea.   
     
     
         30 . The method of  claim 20 , which is a method of treating the KCNQ2-5 channel-related disease.